As the world marks World Tuberculosis Day on March 24th, KAVI-Institute of Clinical Research reaffirms its commitment to raising awareness, promoting early diagnosis, and supporting effective treatment of tuberculosis (TB). Tuberculosis remains one of the world’s deadliest infectious diseases, with millions of new cases reported annually. Despite progress, global reductions in TB incidence remain below targets, highlighting the urgent need for intensified action.

Congratulations to the Director KAVI-ICR, Dr Marianne Mureithi, on being selected for the WomenLift Health 2026 East Africa Leadership Journey!

Among 60 outstanding women leaders across East Africa, Marianne Mureithi will spend the next 12 months deepening her leadership practice through a program intentionally designed for the complex realities of global public health today.

At KAVI-ICR, we are committed to championing women leaders who are driving change in health, and Marianne Mureithi exemplifies that every day.

Dr Marianne W. Mureithi, Director of the KAVI-Institute of Clinical Research (KAVI-ICR)  at the University of Nairobi, is a Co-Investigator on a newly announced CAD 2 million (5-year) international team grant funded by the Canadian Institutes of Health Research (CIHR) under its Bringing Biology to Cancer Prevention programme.

The study will examine how inflammation and hormonal changes influence HPV persistence and cervical cancer risk in menopausal women.